SNDX — SYNDAX PHARMACEUTICALS INC

Ownership history in COMMONWEALTH EQUITY SERVICES, LLC  ·  4 quarters on record

This page tracks every 13F SEC filing in which COMMONWEALTH EQUITY SERVICES, LLC reported a position in SYNDAX PHARMACEUTICALS INC (SNDX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 REDUCED 10,906 -789 -6.7% 0.00% $168K $15.39
2023 Q3 ADDED 11,695 +200 +1.7% 0.00% $170K $14.52
2023 Q2 ADDED 11,495 +605 +5.6% 0.00% $241K $20.93
2023 Q1 INITIATED 10,890 — — 0.00% $230K $21.12
% of Fund (quarterly)    SNDX price (monthly, adj. close)

Other funds also holding SNDX

As of 2025 Q4 — sorted by position size

Elmind Capital, LP 11.5% Kynam Capital Management, LP 3Y 10.81% KINGDON CAPITAL MANAGEMENT, L.L.C. 3Y 7Y 5.87% Aisling Capital Management LP 3Y 7Y 5.78% STEMPOINT CAPITAL LP 4.83% Catalio Capital Management, LP 4.44% Knott David M Jr 3Y 4.04% Lion Point Capital, LP 3Y 7Y 3.91% Eversept Partners, LP 3Y 7Y 3.51% MPM BioImpact LLC 3Y 3.22%
← Back to COMMONWEALTH EQUITY SERVICES, LLC Holdings